Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Mereo BioPharma Group plc - American Depositary Shares
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexeo Therapeutics, Inc. - Common Stock
(NQ:
LXEO
)
2.640
-0.120 (-4.35%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexeo Therapeutics, Inc. - Common Stock
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
May 09, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
May 07, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
April 22, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
April 16, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
March 13, 2024
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor...
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
March 11, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
March 11, 2024
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor...
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
February 05, 2024
From
Lexeo Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
LEXEO Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
December 18, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
December 11, 2023
From
LEXEO Therapeutics
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
